{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:51:20Z","timestamp":1791960680828,"version":"4.3.4"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T00:00:00Z","timestamp":1188950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2007,11,16]]},"DOI":"10.1007\/s00417-007-0637-y","type":"journal-article","created":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T14:41:21Z","timestamp":1188916881000},"page":"1873-1875","source":"Crossref","is-referenced-by-count":22,"title":["Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome"],"prefix":"10.1007","volume":"245","author":[{"given":"Alfredo","family":"Ad\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo P.","family":"Casaroli-Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,5]]},"reference":[{"key":"637_CR1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0161-6420(84)34113-6","volume":"91","author":"JR Olk","year":"1984","unstructured":"Olk JR, Burgess DB, McCormick PA (1984) Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome (POHS): visual prognosis. Ophthalmology 91:1592\u20131602","journal-title":"Ophthalmology"},{"key":"637_CR2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jop.1999.15.425","volume":"15","author":"A Martidis","year":"1999","unstructured":"Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS (1999) Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 15:425\u2013428","journal-title":"J Ocul Pharmacol Ther"},{"key":"637_CR3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.1997.01100160161004","volume":"115","author":"AS Breger","year":"1997","unstructured":"Breger AS, Conway M, del Priore LV et al (1997) Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis. Arch Ophthalmol 115:991\u2013996","journal-title":"Arch Ophthalmol"},{"key":"637_CR4","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(02)01103-X","volume":"109","author":"DA Saperstein","year":"2002","unstructured":"Saperstein DA, Rosenfeld PJ, Bressler NM et al (2002) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one year results of an uncontrolled, prospective case series. Ophthalmology 109:1499\u20131505","journal-title":"Ophthalmology"},{"key":"637_CR5","first-page":"3158","volume":"41","author":"N Kwak","year":"2000","unstructured":"Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158\u20133164","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"637_CR6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"J Shahar","year":"2006","unstructured":"Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intarvitreal injection of bevacizumab (Avastin). Retina 26:262\u2013269","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0637-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-007-0637-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-007-0637-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:33Z","timestamp":1559072433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-007-0637-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,5]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,11,16]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s00417-007-0637-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,5]]}}}